[{"uuid": "e1a9f6e5-63fe-3b16-ac47-16fcbe69ccd6", "title": "Innovations in Sustainable Electronics Manufacturing", "publisher": "ACCESS Newswire", "link": "https://finance.yahoo.com/news/innovations-sustainable-electronics-manufacturing-140000771.html", "providerPublishTime": 1738072800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/8yUhJ9XIBPfXxnZKGJf_cg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/fd0b740901f3086b93028e6be3e718b2", "width": 400, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/boPAGu668keGMvn_0.NrHA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/accesswire.ca/fd0b740901f3086b93028e6be3e718b2", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "a866f776-c0b0-37e7-949c-649b04a76191", "title": "AI and blockchain in mining: unearthing value in the emergent with the emerging", "publisher": "Mining Technology", "link": "https://finance.yahoo.com/m/a866f776-c0b0-37e7-949c-649b04a76191/ai-and-blockchain-in-mining%3A.html", "providerPublishTime": 1737030762, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/eURhWWD3ajkp5NMMBlIlzw--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mining_technology_700/181239b1209c46029d6cccd3d3dc4910", "width": 1440, "height": 810, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ANj0ZTKXm2yDVc9TK2rH0A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mining_technology_700/181239b1209c46029d6cccd3d3dc4910", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GLDAF"]}, {"uuid": "5b497e68-7a37-3ff0-9850-26ad3c3c4047", "title": "Retraced Teams With R-pac for Traceability Ahead of DPP\u00a0Rollout", "publisher": "Sourcing Journal", "link": "https://finance.yahoo.com/m/5b497e68-7a37-3ff0-9850-26ad3c3c4047/retraced-teams-with-r-pac-for.html", "providerPublishTime": 1736965800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/0A3cDzpN1QtsinI1JuMidg--~B/aD0xMDEzO3c9MTgwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/sourcing_journal_735/5ad993a0f43abb75d17745bbe1fc61d7", "width": 1800, "height": 1013, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/X4VxQOz3YZ_24UcLZKKVJw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/sourcing_journal_735/5ad993a0f43abb75d17745bbe1fc61d7", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "41f45b4d-01bf-37b2-9f41-99e97dac036b", "title": "Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/ardelyx-ardx-moves-16-0-140700020.html", "providerPublishTime": 1736863620, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/dREdZrR4qB4B1dW7vORwmw--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/291aa8ceddf93457e286f5d0d49ebc36", "width": 900, "height": 588, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Dmj4XNUWqRB6D56iE7bxxw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/291aa8ceddf93457e286f5d0d49ebc36", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ARDX", "ESPR"]}, {"uuid": "2632d221-279e-312a-a159-a90102d4cb20", "title": "Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/esperion-host-virtual-key-opinion-130000698.html", "providerPublishTime": 1736427600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/cWzOPCk90tLJEOndzKo8yw--~B/aD0xMTM2O3c9MzYxNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 3616, "height": 1136, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/EYChm7SOurWR4nfXnXYqDw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ESPR"]}, {"uuid": "3922d19c-6f83-39dc-b12a-3d5a947becc3", "title": "Fortude partners with Ettos to enhance sustainability across fashion supply chains", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/fortude-partners-ettos-enhance-sustainability-123900847.html", "providerPublishTime": 1736253540, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/0YHz5EGjkmZaTjNIwTvxKg--~B/aD03Nzk7dz0xMzg0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6f60749a2fb2c66d17be6a04ecd72dc7", "width": 1384, "height": 779, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/b14hEL0M3VRK1GvOwz7MBA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/6f60749a2fb2c66d17be6a04ecd72dc7", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "bc821ece-fb39-3b2b-84bd-53a9605d078f", "title": "5 fashion industry trends to watch in 2025", "publisher": "Fashion Dive", "link": "https://finance.yahoo.com/m/bc821ece-fb39-3b2b-84bd-53a9605d078f/5-fashion-industry-trends-to.html", "providerPublishTime": 1736333040, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/A2ARHjCtXSScr_4OAwZUQg--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/fashion_dive_531/c44cdfa0c2ee362a6c9784b20116b47c", "width": 1600, "height": 900, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/aoSFlRCy3cE6w78OcPyFhw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/fashion_dive_531/c44cdfa0c2ee362a6c9784b20116b47c", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "151dccad-ce34-3a51-af94-9cf736bd2957", "title": "Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/esperion-participate-upcoming-43rd-annual-130000279.html", "providerPublishTime": 1735822800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/cWzOPCk90tLJEOndzKo8yw--~B/aD0xMTM2O3c9MzYxNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 3616, "height": 1136, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/EYChm7SOurWR4nfXnXYqDw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ESPR"]}, {"uuid": "722a7453-5223-33f8-8d11-25f3f01db66e", "title": "ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/espr-files-drug-submissions-nexletol-150600595.html", "providerPublishTime": 1733238360, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.vcXZvNbnFvDkPdENtrKng--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c", "width": 620, "height": 413, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/T0yuNkWmZR3Cm7Bxzq6szA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ESPR"]}, {"uuid": "c665ac33-d75c-3405-b27b-a25460095110", "title": "Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/esperion-therapeutics-completes-financing-deals-133436358.html", "providerPublishTime": 1734528876, "type": "STORY", "relatedTickers": ["ESPR"]}, {"uuid": "1b3eae77-4cbc-3f9d-b472-8bbfdb7076bb", "title": "Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/esperion-therapeutics-espr-reports-q3-121008891.html", "providerPublishTime": 1730981408, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be", "width": 900, "height": 594, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/UfNPsRi0m54aItY_qLFDbg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ESPR"]}, {"uuid": "439f7670-a3f8-3dad-97a2-b06f64358a13", "title": "Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/cantor-fitzgerald-initiates-esperion-therapeutics-123649189.html", "providerPublishTime": 1734439009, "type": "STORY", "relatedTickers": ["ESPR"]}, {"uuid": "307bf417-e197-3458-a31c-bf7c9eaa1832", "title": "Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/esperions-q3-loss-wider-expected-155800023.html", "providerPublishTime": 1730995080, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pa5q6Axi5bBp9pCuwXBcUg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ESPR"]}, {"uuid": "07e07487-eca0-30cf-864d-fa3d72098fce", "title": "Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/esperion-strengthens-balance-sheet-closing-120000330.html", "providerPublishTime": 1734523200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/cWzOPCk90tLJEOndzKo8yw--~B/aD0xMTM2O3c9MzYxNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 3616, "height": 1136, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/EYChm7SOurWR4nfXnXYqDw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ESPR"]}, {"uuid": "08f3bd1d-f8ab-3892-b363-afb6837e1127", "title": "Esperion Swaps New Notes, Cash for $210 Million of Convertible Debt; Shares Slump Pre-Bell", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/esperion-swaps-notes-cash-210-142859102.html", "providerPublishTime": 1734100139, "type": "STORY", "relatedTickers": ["ESPR"]}, {"uuid": "b97839f4-edc3-3256-879e-24319c4197a6", "title": "Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/esperion-therapeutics-signs-licensing-deal-144721055.html", "providerPublishTime": 1734014841, "type": "STORY", "relatedTickers": ["ESPR"]}, {"uuid": "1e2b2f90-faa3-318a-91c7-2026d2ed71eb", "title": "Esperion Announces $210 Million Convertible Debt Financing", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/esperion-announces-210-million-convertible-110000526.html", "providerPublishTime": 1734087600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/cWzOPCk90tLJEOndzKo8yw--~B/aD0xMTM2O3c9MzYxNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 3616, "height": 1136, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/EYChm7SOurWR4nfXnXYqDw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ESPR"]}, {"uuid": "b87d6119-e7d5-35d1-986c-456212cc2acf", "title": "Esperion Partners with Neopharm to Commercialize NEXLETOL\u00ae (bempedoic acid) and NEXLIZET\u00ae (bempedoic acid and ezetimibe) in Israel", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/esperion-partners-neopharm-commercialize-nexletol-130000597.html", "providerPublishTime": 1734008400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/cWzOPCk90tLJEOndzKo8yw--~B/aD0xMTM2O3c9MzYxNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 3616, "height": 1136, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/EYChm7SOurWR4nfXnXYqDw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d6b6d330931a2c020c55a96ce82ba685", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ESPR"]}, {"uuid": "663edee1-cf15-3886-b0f3-6721ad57bafc", "title": "Esperion Therapeutics' Bempedoic Acid Submitted for Approval in Japan by Otsuka Pharmaceutical", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/esperion-therapeutics-apos-bempedoic-acid-140338338.html", "providerPublishTime": 1732629818, "type": "STORY", "relatedTickers": ["ESPR", "OTSKY"]}, {"uuid": "273ed57f-403f-3ac0-9d27-20082c6df283", "title": "Esperion Therapeutics Files Applications for Non-Statin Medications in Canada", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/esperion-therapeutics-files-applications-non-133014493.html", "providerPublishTime": 1733146214, "type": "STORY", "relatedTickers": ["ESPR"]}]